Falciparum malaria: Current therapeutic challenges

Current Opinion in Infectious Diseases

Volumn 17, Issue 5, 2004, Pages 405-412

  Maitland, Kathryn ^a,b,e   Makanga, Michael ^a,c   Williams, Thomas N ^a,d  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e CGMRC KEMRI   (Kenya)

Author keywords

Antimalarial; Autopsy; Drug resistance; Malaria; Pathogenesis; Treatment

Indexed keywords

AMODIAQUINE; ARTEETHER; ARTEKIN; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CHLOROQUINE; CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; CLINDAMYCIN; DAPSONE; DOXYCYCLINE; FANSIDAR; HALOFANTRINE; MACROLIDE; MEFLOQUINE; PYRIMETHAMINE; QUININE; SULFADOXINE; SULFALENE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HEARING IMPAIRMENT; HEPATITIS; HUMAN; MALARIA; MALARIA FALCIPARUM; NEUROTOXICITY; NEUTROPENIA; REVIEW;

ANIMALS; ANTIMALARIALS; CHILD; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 6444228720     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200410000-00004     Document Type: Review

References (95)

1. Guerin PJ, Olliaro P, Nosten F, et al. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2002; 2:564-573.
2. Snow R, Craig H, Newton C, Steketee R. The public health burden of Plasmodium falciparum malaria in Africa: Deriving the numbers. Bethesda, Maryland: Fogarty International Center, National Institutes of Health; August 2003. Working Paper No. 11. In this in-depth review, the authors provide an overview of morbidity and mortality patterns in sub-Saharan Africa. Recent evidence is re-analysed to provide estimates of the direct health consequences of malaria infection in Africa and to examine the indirect contribution of malaria infection on mortality, other cause morbidity and disability.
3. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 94 (Suppl 1):S1-S90.
4. Adelman CC, Norris J. WHO. The Global Fund, and medical malpractice in malaria treatment. Lancet 2004; 363(9415):1161.
5. Attaran A, Barnes KI, Curtis C, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004; 363:237-240. This is a provocative review of the progress of the World Health Organization's Roll Back Malaria programme. In particular, the authors single out projects that involve inappropriate drug treatment.
6. de Vries PJ, Kager PA, Borgdorff MW. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004; 363:1161.
7. Nafo-Traore F. Response to accusations of medical malpractice by WHO and the Global Fund. Lancet 2004; 363:397.
8. Nantulya VM, Liden J. Response to accusations of medical malpractice by WHO and the Global Fund. Lancet 2004; 363:397-398.
9. Watkins B, Kokwaro G, Galinski M, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004; 363:1161-2.
10. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113:1084-1092. This discusses the genetic basis and the role of immunity in the development and spread of resistance. The author also discusses newer combination therapies.
11. White N, Nosten F, Bjorkman A, et al. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 2004; 363:1160.
12. Sodahlon YK, Agbo K, Morgan K, et al. Chloroquine efficacy in the treatment of uncomplicated malaria at three sentinel sites in northern Togo. Ann Trop Med Parasitol 2003; 97:775-782.
13. Molta NB, Oguche S, Pam SD, et al. Amodiaquine treatment of uncomplicated malaria in children, in an area of chloroquine-resistant Plasmodium falciparum in north-central Nigeria. Ann Trop Med Parasitol 2003; 97:663-669.
14. van den Broek IV, Gatkoi T, Lowoko B, et al. Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated Plasmodium falciparum malaria in Upper Nile, south Sudan. Trans R Soc Trop Med Hyg 2003; 97:229-235.
15. Dorsey G, Vlahos J, Kamya MR, et al. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. J Infect Dis 2003; 188:1231-1238. This study investigates response to treatment and the prevalence of resistance-conferring mutations in recrudescent infections in children treated with sulfadoxine-pyrimethamine, sulphadoxine-pyrimethamine plus amodiaquine, or sulphadoxine-pyrimethamine plus artesunate. Despite frequent recrudescence in the sulphadoxine-pyrimethamine group, failure in the sulphadoxine-pyrimethamine plus amodioquine group was uncommon, suggesting that it may prolong the therapeutic life span of available treatment regimens.
16. Gonzalez IJ, Padilla JO, Giraldo LE, Saravia NG. Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Marino, Colombia, 1999-2002. Biomedica 2003; 23:38-46.
17. Olliaro P, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst Rev 2003(2):CD000016. Evidence is presented to support the continued use of amodiaquine to treat uncomplicated malaria, although local drug resistance patterns need to be considered.
18. Olliaro PL, Taylor WR. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review. J Postgrad Med 2004; 50:40-44. This review summarizes current antimalarial drug developments and recent clinical research into artemesinin based combinations.
19. Testa CA, Brown MJ. The methylerythritol phosphate pathway and its significance as a novel drug target. Curr Pharm Biotechnol 2003; 4:248-259.
20. Wiesner J, Borrmann S, Jomaa H. Fosmidomycin for the treatment of malaria. Parasitol Res 2003; 90 (Suppl 2):S71-S76.
21. Padmanaban G. Drug targets in malaria parasites. Adv Biochem Eng Biotechnol 2003; 84:123-141.
22. Le Roch KG, Zhou Y, Blair PL, et al. Discovery of gene function by expression profiling of the malaria parasite life cycle. Science 2003; 301:1503-1508. These authors report on microarray technology to generate expression profiles of human and mosquito stages of the malaria parasite's life cycle.
23. Lell B, Ruangweerayut R, Wiesner J, et al. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob Agents Chemother 2003; 47:735-738.
24. Borrmann S, Adegnika AA, Matsiegui PB, et al. Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis 2004; 189:901-908.
25. Karunajeewa H, Lim C, Hung TY, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin(R) in Cambodian children and adults with malaria. Br J Clin Pharmacol 2004; 57:93-99.
26. Joet T, Krishna S. The hexose transporter of Plasmodium falciparum is a worthy drug target. Acta Trap 2004; 89:371-374.
27. Peters W. Recent advances in antimalarial chemotherapy and drug resistance. Adv Parasitol 1974; 12:69-114.
28. Ezard N, Burns M, Lynch C, et al. Efficacy of chloroquine in the treatment of uncomplicated Plasmodium falciparum infection in East Timor, 2000. Acta Trop 2003; 88:87-90.
29. Zucker JR, Ruebush TK 2nd, Obonyo C, et al. The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg 2003; 68:386-390.
30. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27:25-61. This is a comprehensive review of the spectrum of the adverse drug reactions and toxicity to both commonly used and newer antimalarial drugs.
31. Thomas F, Erhart A, D'Alessandro U. Can amodiaquine be used safely during pregnancy? Lancet Infect Dis 2004; 4:235-239.
32. Rwagacondo CE, Niyitegeka F, Sarushi J, et al. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sutfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg 2003; 68:743-747.
33. Abacassamo F, Enosse S, Aponte JJ, et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trap Med Int Health 2004; 9:200-208. This paper examines the therapeutic efficacy of each regime both individually and in combination in an area where chloroquine resistance is common. Any combination resulted in 100% cure at day 14 for children with uncomplicated malaria.
34. Checchi F, Piola P, Kosack C, et al. Antimalarial efficacy of sulfadoxinepyrimethamine, amodiaquine and a combination of chbroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda. Trap Med Int Health 2004; 9:445-450.
35. Gssasira AF, Dorsey G, Nzarubara B, et al. Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trap Med Hyg 2003; 68:127-132.
36. Le Bras J. Mechanisms and dynamics of drug resistance in Plasmodium falciparum. Bull Soc Pathol Exot 1999; 92:236-241.
37. Le Bras J, Durand R. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam Clin Pharmacol 2003; 17:147-153.
38. Bwijo B, Kaneko A, Takechi M, et al. High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Trop 2003; 85:363-373.
39. Newman RD, Parise ME, Slutsker L, et al. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health 2003; 8:488-506.
40. van Eijk AM, Ayisi JG, ter Kuile FO, et al. Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. Trop Med Int Health 2004; 9:351-360.
41. Lang T, Greenwood B. The development of Lapdap, an affordable new treatment for malaria. Lancet Infect Dis 2003; 3:162-168. This discusses the development of Lapdap through public-private partnership and speculates on the treatment niche for Lapdap once it receives regulatory approval.
42. Winstanley P. Chbrproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop Med Int Health 2001; 6:952-654.
43. Mutabingwa TK, Maxwell CA, Sia IG, et al. A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infections in Tanzania. Trans R Soc Trop Med Hyg 2001; 95:433-438.
44. Nosten F, Brasseur P. Combination therapy for malaria: the way forward? Drugs 2002; 62:1315-1329.
45. Nosten F, Ashley E. The detection and treatment of Plasmodium falciparum malaria: time for change. J Postgrad Med 2004; 50:35-39.
46. Danis M, Bricaire F. The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria. Fundam Clin Pharmacol 2003; 17:155-160.
47. Kager PA. Three newly registered drugs in the Netherlands for the treatment and chemoprophylaxis of malaria: atovaquone-proguanil, artemether-lumefantrine and artemotil [in Dutch]. Ned Tijdschr Geneeskd 2003; 147:291-295.
48. Omari AA, Preston C, Garner P. Artemether-lumefantrine for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev 2003; (2):CD003125.
49. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999; 37:105-125.
50. Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999; 60:936-942.
51. van Vugt M, Looareesuwan S, Wilairatana P, et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94:545-548.
52. Makanga M, Falade C, Premji Z, et al. Pharmacokinetics of the 6-dose of coartemether (artemether-lumefantrine) in African infants and children with acute uncomplicated falciparum malaria [abstract]. In: Malaria Drug Development; 3-7 December 2003; Philadelphia. Northbrook, Illinois: American Society of Tropical Medicine and Hygiene; 2003; p. 153.
53. Premji Z, Falade C, Makanga M, et al. Efficacy of co-artemether (artemetherlumefantrine), 6-dose regime, in African infants and children with acute uncomplicated falciparum malaria [abstract]. In: Malaria Drug Development; 3-7 December 2003; Philadelphia. Northbrook, Illinois: American Society of Tropical Medicine and Hygiene; 2003; p. 206.
54. Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2001; 64:247-256.
55. Bakshi R, Hermeling-Fritz I, Gathmann I, Alten E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg 2000; 94:419-424.
56. Krudsood S, Chalermrut K, Pengruksa C, et al. Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health 2003; 34:316-321.
57. Kshirsagar NA, Gogtay NJ, Moorthy NS, et al. A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in India. Am J Trop Med Hyg 2000; 62:402-408.
58. Falade C, Makanga M, Premji Z, et al. Co-artemether (artemether- lumefantrine), safety profile on antimalarial combination in African infants and children with acute uncomplicated falciparum malaria when treated with the 6-dose regime [abstract]. In: Malaria Drug Development; 3-7 December 2003; Philadelphia. Northbrook, Illinois: American Society of Tropical Medicine and Hygiene; 2003; p. 207.
59. Toovey S, Jamieson A. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 2004; 98:261-267; discussion 268-269.
60. Denis MB, Davis TM, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 2002; 35:1469-1476.
61. Hung TY, Davis TM, Ilett KF, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004; 57:253-262. Fever clearance was achieved within 24 h and parasite clearance within 72 h in Cambodian patients treated with Artekin. The t1/2,z was long at 23 days (19-28 days).
62. Tran TH, Dolecek C, Pham PM, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004; 363:18-22. In an area with multidrug resistant falciparum malaria 3-day regimes of this cheap oral combination therapy lead to a 56-day cure rate of 97%.
63. Atovaquone + proguanil: new preparation. Second-line antimalarial combination. Prescrire Int 2002; 11:131-136.
64. McKeage K, Scott L. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs 2003; 63:597-623. Malarone is highly effective against drug-resistant strains of P. falciparum, and cross-resistance has not been observed between atovaquone and other antimalarial agents. Cost and the need for daily dosing limit its widespread use for travel prophylaxis.
65. Winstanley PA, Ward SA, Snow RW. Clinical status and implications of antimalarial drug resistance. Microbes Infect 2002; 4:157-164.
66. Borrmann S, Faucher JF, Bagaphou T, et al. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. Clin Infect Dis 2003; 37:1441-1447.
67. Marra F, Salzman JR, Ensom MH. Atovaquone-proguanil for prophylaxis and treatment of malaria. Ann Pharmacother 2003; 37:1266-1275.
68. Noedl H, Wernsdorfer WH, Krudsood S, et al. Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum in Thailand. Acta Trop 2001; 80:39-44.
69. Pukrittayakamee S, Chantra A, Vanijanonta S, et al. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 2000; 44:2395-2398.
70. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004; 10:143-5. This autopsy report challenges the clinical picture of severe malaria in that it demonstrates that although a number of children were considered to have clinical features of severe malaria, up to 25% died of other causes. The authors suggest that this has implications for clinical trials and immunogenetic studies designed to examine malaria-specific disease associations.
71. Lewallen S, Harding SP, Ajewole J, et al. A review of the spectrum of clinical ocular fundus findings in P. falciparum malaria in African children with a proposed classification and grading system. Trans R Soc Trop Med Hyg 1999; 93:619-622.
72. Beare NA, Southern C, Kayira K, et al. Visual outcomes in children in Malawi following retinopathy of severe malaria. Br J Ophthalmol 2004; 88:321-324. Children were examined during admission and 1 month after discharge. Visual acuity was similar in children who had malaria retinopathy (macular whitening) and those without macular whitening. Following an episode of cerebral malaria approximately 4% of children developed cortical blindness.
73. Pongponratn E, Turner GD, Day NP, et al. An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg 2003; 69:345-359. This describes the largest post-mortem series to date including hundreds of sections from the brains and kidneys of Vietnamese and Thai adults. The studies provided supportive evidence for sequestration of the infected erythrocyte as the primary aetiological event in severe malaria.
74. Torre D, Speranza F, Martegani R. Role of proinflammatory and anti-inflammatory cytokines in the immune response to Plasmodium falciparum malaria. Lancet Infect Dis 2002; 2:719-720.
75. Kojima S, Nagamine Y, Hayano M, et al. A potential role of interleukin 18 in severe falciparum malaria. Acta Trop 2004; 89:279-284.
76. Chaiyaroj SC, Rutta AS, Muenthaisong K, et al. Reduced levels of transforming growth factor-beta1, interleukin-12 and increased migration inhibitory factor are associated with severe malaria. Acta Trop 2004; 89:319-327.
77. McDevitt MA, Xie J, Gordeuk V, Bucala R. The anemia of malaria infection: role of inflammatory cytokines. Curr Hematol Rep 2004; 3:97-106.
78. Nagamine Y, Hayano M, Kashiwamura S, et al. Involvement of interleukin-18 in severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2003; 97:236-241.
79. Chaisavaneeyakorn S, Othoro C, Shi YP, et al. Relationship between plasma Interleukin-12 (IL-12) and IL-18 levels and severe malarial anemia in an area of holoendemicity in western Kenya. Clin Diagn Lab Immunol 2003; 10:362-366.
80. Clark IA, Cowden WB. The pathophysiology of falciparum malaria. Pharmacol Ther 2003; 99:221-260. This in-depth review focuses on the evolutionary cytokine model of severe malaria, which supports the notion that severe malaria results from an overstimulation immune response leading to an imbalance in pro-inflammatory and anti-inflammatory cytokine profiles.
81. Combes V, Taylor TE, Juhan-Vague I, et al. Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma. JAMA 2004; 291:2542-2544. Data are presented that demonstrate the presence of the endothelial microparticles in children with severe malaria, evidence for the role of endothelial activation in the pathophsyiology.
82. Clark IA, Awburn MM, Whitten RO, et al. Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. Malar J 2003; 2(1):6. Further results from the Malawian autopsy study provided data on migration inhibitory factor and inducible nitric oxide synthase in tissues from children who had died of cerebral malaria (n = 32), non-malarial disease (n= 10) and control tissues from Australian adults. Migration inhibitory factor and inducible nitric oxide synthase staining was compared with other pathological features including sequestration and perivascular haemorrhages.
83. Clark IA, Awburn MM, Harper CG, et al. Induction of HO-1 in tissue macrophages and monocytes in fatal falciparum malaria and sepsis. Malar J 2003; 2:41. Haemoxygenase-1 was examined from pathological sections in 40 Malawian children comprising 32 with cerebral malaria, five with bacterial diseases with coma and three deaths uncomplicated by coma. Control tissues were from Australian adults. Monocytes and tissue macrophages from brain, lung, liver and spleen (data not reported) were examined for haemoxygenase-1.
84. Krishnan A, Karnad DR. Severe falciparum malaria: an important cause of multiple organ failure in Indian intensive care unit patients. Crit Care Med 2003; 31:2278-2284.
85. Koh KH, Chew PH, Kiyu A. A retrospective study of malaria infections in an intensive care unit of a general hospital in Malaysia. Singapore Med J 2004; 45:28-36.
86. Vogetseder A, Ospelt C, Reindl M, et al. Time course of coagulation parameters, cytokines and adhesion molecules in Plasmodium falciparum malaria. Trop Med Int Health 2004; 9:767-773. Evidence is presented supporting a role for impairments of coagulation and cytokine activation in the severity of falciparum disease.
87. Bruneel F, Hocqueloux L, Alberti C, et al. The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. Am J Respir Crit Care Med 2003; 167:684-689.
88. Dondorp AM, Pongponratn E, White NJ. Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop 2004; 89:309-317.
89. Krishna S, Waller DW, ter Kuile F, et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994; 88:67-73.
90. Levin M, editor. Paediatric Emergencies. 2nd ed. London: Butterworths; 1987.
91. Carcillo JA, Fields AI. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365-1378.
92. Maitland K, Levin M, English M, et al. Falciparum malaria in Kenyan children: evidence for hypovolaemia. QJM 2003; 96:427-34. This is a retrospective analysis of clinical correlates with fatal outcome in children admitted with severe malaria. Many of the correlates associated with a fatal outcome would be regarded as evidence for hypovolaemia in critically-ill children, irrespective of cause.
93. Maitland K, Pamba A, Newton CR, Levin M. Response to volume resuscitation in children with severe malaria. Pediatr Crit Care Med 2003; 4:426-431. Phase I trials of volume expansion in Kenyan children with severe malaria complicated by acidosis suggested that volume depletion (hypovolaemia) is the main cause of acidosis in severe childhood malaria.
94. Grimwade K, French N, Mthembu D, Gilks C. Polyuria in association with Plasmodium falciparum malaria in a region of unstable transmission. Trans R Soc Trop Med Hyg 2004; 98:255-260. In this retrospective study of 175 adult cases of severe malaria no significant differences were found between the polyuric and non-polyuric cases at presentation and mortality in both groups was similar. This contrasts sharply with areas in the world where transmission of malaria is unstable and adults develop severe disease, for whom acute renal failure with ollguria is relatively common and is a major contributor to mortality.
95. Maitland K, Pamba A, Newton CR, et al. Hypokalemia in children with severe falciparum malaria. Pediatr Crit Care Med 2004; 5:81-85. Potassium replacement therapy should be considered in children with severe malaria, especially in hospitals where monitoring of potassium is possible.